Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07130097 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants
A Phase 1 study of Healthy Participant, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07130097: Completed Phase 1 study of Healthy Participant, sponsored by Pfizer.
NCT07130097 is a Phase 1 study of Healthy Participant that has completed, run by Pfizer. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07130097, a Phase 1 study of Healthy Participant, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of the current PF-07220060 tablet formulation and the proposed higher drug load tablet that is already available in the market. The study is seeking participants who are: * Healthy males and females aged 18 to 65 years * Willing and able to comply with all scheduled visits, treatment plan, lifestyle considerations, and other study procedures. * Body Mass Index of 17.5-30.5 kilogram per meter squared (kg/m2); and a total body weight of more than 50 kilograms (kg) \[110 pounds (lb)\]. Participants in the study will receive a single dose of PF-07220060 by mouth after a meal, following at least 7 days, the participant will then receive another dose of PF-07220060. Each dose received by the participant will be a different tablet formulation, and the sequence of tablet formulations given will be random (just like a flipside of the coin). The study will help the team understand how the difference in tablet formulation may, or may not, affect how the medicine is absorbed, processed, and removed by the body. Participants will remain in the study clinic for at least 13 days and will have one follow-up contact.
Primary Outcome
AUClast was area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (If data does not permit reporting of AUCinf). The geometric coefficient of variation is expressed in percentage. The ratio (Test/Reference) of adjusted means and 90% CI are then expressed as percentages.
Conditions Studied
Interventions
- DRUG PF-07220060
Study Locations (1)
Connecticut
- Pfizer Clinical Research Unit - New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-08-14 |
| Est. Completion | 2025-11-18 |
| Phase | Phase 1 |
What the finished NCT07130097 record still lists
NCT07130097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Healthy Participant appearing as the primary indexed condition, and to 1 intervention - of which PF-07220060 is the first listed.
NCT07130097 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07130097 about?
NCT07130097 is a clinical study titled "A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants". The purpose of this study is to understand bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of the current PF-07220060 tablet formulation and the proposed higher drug load tablet that is already available in the market. The ...
What is the current status of trial NCT07130097?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2025-08-14. Estimated completion is 2025-11-18.
What conditions does trial NCT07130097 study?
This clinical trial studies the following conditions: Healthy Participant.
What interventions are being tested in trial NCT07130097?
The interventions under investigation include: PF-07220060 (DRUG).
Who is sponsoring clinical trial NCT07130097?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07130097 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07130097's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI